Biotech · Cambridge, MA · Founded 2022 · Privately Held (backing)
Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases. Merida Biosciences is based in Cambridge, MA and was founded in 2022. It was valued at $228 million at its early-stage round in Apr 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $121 million Series A in Apr 2025.
PMV mark · valuation
$228.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$154.0M
Last round
Series A
Apr 2025
No prints on record
No secondary trades in Merida Biosciences shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Merida Biosciences with a free account
·Everyone on the team, board and advisors included
·Watch Merida Biosciences: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Merida Biosciences stock.
